Latest1 information on COVID-19
©2022 Stanford Medicine
Treatment of Schizoaffective Disorder Using Mifepristone
Not Recruiting
Trial ID: NCT00725270
Purpose
This study tests the hypothesis that mifepristone will diminish cognitive distortion and
alleviate psychosis in patients with schizoaffective disorder.
Official Title
Treatment of Schizoaffective Disorder Using Mifepristone
Stanford Investigator(s)
Hugh Brent Solvason PhD MD
Clinical Professor, Psychiatry and Behavioral Sciences
Jennifer Keller
Clinical Professor, Psychiatry and Behavioral Sciences
Eligibility
Inclusion Criteria:The subjects will be 30 inpatients or outpatients with schizoaffective
disorder. Exclusion Criteria:Subjects must be between the ages of eighteen and seventy-five
without major medical problems.
Intervention(s):
drug: Mifepristone
drug: Placebo Oral Tablet
drug: Placebo Oral Tablet
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jessica Hawkins
6507238323